Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.
2.

Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.

Cho IH, Kong EJ.

Nucl Med Mol Imaging. 2017 Sep;51(3):217-226. doi: 10.1007/s13139-016-0446-5. Epub 2016 Aug 30. Review.

PMID:
28878847
3.

DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response.

Thibault G, Tudorica A, Afzal A, Chui SY, Naik A, Troxell ML, Kemmer KA, Oh KY, Roy N, Jafarian N, Holtorf ML, Huang W, Song X.

Tomography. 2017 Mar;3(1):23-32. doi: 10.18383/j.tom.2016.00241.

4.

Recent Advances in the Neoadjuvant Treatment of Breast Cancer.

Rubovszky G, Horváth Z.

J Breast Cancer. 2017 Jun;20(2):119-131. doi: 10.4048/jbc.2017.20.2.119. Epub 2017 Jun 26. Review.

5.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:
28688082
6.

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, Sharma VP, Xue EA, Cheng E, D'Alfonso TM, Jones JG, Anampa J, Rohan TE, Sparano JA, Condeelis JS, Oktay MH.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaan0026. doi: 10.1126/scitranslmed.aan0026. Erratum in: Sci Transl Med. 2017 Jul 19;9(399):.

7.

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).

van Roozendaal LM, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Boersma LJ, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, Van de Vijver KKBT, de Vries J, Westenberg AH, Kessels AGH, de Wilt JHW, Smidt ML.

BMC Cancer. 2017 Jul 1;17(1):459. doi: 10.1186/s12885-017-3443-x.

8.

Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.

Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M.

Ann Surg Oncol. 2017 Sep;24(9):2556-2562. doi: 10.1245/s10434-017-5898-z. Epub 2017 May 30.

PMID:
28560596
9.

Cure modeling in real-time prediction: How much does it help?

Ying GS, Zhang Q, Lan Y, Li Y, Heitjan DF.

Contemp Clin Trials. 2017 Aug;59:30-37. doi: 10.1016/j.cct.2017.05.012. Epub 2017 May 22.

PMID:
28545934
10.

Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.

Anderson PG, Kalli S, Sassaroli A, Krishnamurthy N, Makim SS, Graham RA, Fantini S.

Acad Radiol. 2017 Oct;24(10):1240-1255. doi: 10.1016/j.acra.2017.03.020. Epub 2017 May 19.

PMID:
28532642
11.

Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.

Guerrero-Zotano AL, Arteaga CL.

Cancer Discov. 2017 Jun;7(6):561-574. doi: 10.1158/2159-8290.CD-17-0228. Epub 2017 May 11. Review.

PMID:
28495849
12.

Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.

Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Mukai H, Yasuda Y.

Oncol Lett. 2017 Mar;13(3):1731-1740. doi: 10.3892/ol.2017.5628. Epub 2017 Jan 19.

13.

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.

Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de Roquancourt A, Bertheau P, Verneuil L, Feugeas JP, Espié M, Janin A.

Oncotarget. 2017 May 23;8(21):35205-35221. doi: 10.18632/oncotarget.16925.

14.

Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.

Cochran JM, Chung SH, Leproux A, Baker WB, Busch DR, DeMichele AM, Tchou J, Tromberg BJ, Yodh AG.

Phys Med Biol. 2017 Jun 21;62(12):4637-4653. doi: 10.1088/1361-6560/aa6cef. Epub 2017 Apr 12.

PMID:
28402286
15.

Rhomboid Flap Technique in Breast-conserving Surgery: An Alternative Method for the Reconstruction of Lumpectomy Defects.

Menekşe E, Özyazıcı S, Karateke F, Turan Ü, Kuvvetli A, Gökler C, Özdoğan M, Önel S.

J Breast Health. 2015 Oct 1;11(4):186-191. doi: 10.5152/tjbh.2015.2572. eCollection 2015 Oct.

16.

Evaluation of Neoadjuvant Chemotherapy Response with Dynamic Contrast Enhanced Breast Magnetic Resonance Imaging in Locally Advanced Invasive Breast Cancer.

Gezer NS, Orbay Ö, Balcı P, Durak MG, Demirkan B, Saydam S.

J Breast Health. 2014 Apr 1;10(2):111-118. doi: 10.5152/tjbh.2014.2035. eCollection 2014 Apr.

17.

Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know.

Teven CM, Schmid DB, Sisco M, Ward J, Howard MA.

Eplasty. 2017 Feb 21;17:e7. eCollection 2017.

18.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

19.

Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.

Tan QW, Luo T, Zheng H, Tian TL, He P, Chen J, Zeng HL, Lv Q.

Chin J Cancer. 2017 Mar 7;36(1):27. doi: 10.1186/s40880-017-0196-5.

20.

Personalized chemotherapy selection for breast cancer using gene expression profiles.

Yu K, Sang QA, Lung PY, Tan W, Lively T, Sheffield C, Bou-Dargham MJ, Liu JS, Zhang J.

Sci Rep. 2017 Mar 3;7:43294. doi: 10.1038/srep43294.

Supplemental Content

Support Center